Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 245

The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.

New Anticoagulants

Open access
Eikelboom, John W., Weitz, Jeffrey I.·2010·Circulation

Abstract

T hromboembolism involving the arterial or venous circu- lation or arising from the heart is a common cause of morbidity and mortality.Rapidly acting parenteral anticoagulants, such as heparin, are used for the prevention and initial treatment of thromboembolism and during revascularization procedures, 1 whereas the slower-acting vitamin K antagonists (VKAs) are used for long-term therapy. 2 The introduction of low-molecular-weight heparin (LMWH) and fondaparinux has simplified parenteral anticoagulant therapy, and these agents have replaced heparin for many indications.3 Development of new oral anticoagulants to replace VKAs has been slower than that of parenteral agents.Ximelagatran, an oral thrombin inhibitor, was briefly licensed in Europe but was withdrawn in 2006 because of potential hepatic toxicity.4 Although this set the field back for several years, the situation has changed with the recent introduction of dabigatran etexilate, a new oral thrombin inhibitor, and rivaroxaban, an oral factor Xa (fXa) inhibitor.3 Licensed in Europe and Canada for prevention of venous thromboembolism (VTE) in patients undergoing hip or knee arthroplasty, dabigatran etexilate and rivaroxaban streamline out-of-hospital thromboprophylaxis because the drugs can be given once daily in fixed doses without coagulation monitoring.The greater unmet medical need, however, is to find a replacement for VKAs for long-term therapy, particularly stroke prevention in patients with atrial fibrillation (AF).The results of the Randomized Evaluation of Long-Term Anticoagulant Therapy (RE-LY) trial, which compared dabigatran etexilate with warfarin for stroke prevention in patients with AF, demonstrate that the new oral anticoagulants have the potential to be more effective and safer than VKAs. 5 If these results are replicated with other agents and in additional clinical settings, then oral thrombin and fXa inhibitors will soon replace VKAs.This article (1) outlines the limitations of established parenteral and oral anticoagulants, (2) describes the potential advantages of the new agents, (3) briefly reviews the pharmacology and clinical trial results with new anticoagulants in advanced stages of development, and (4) provides perspective on the opportunities and challenges with the new parenteral and oral anticoagulants.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1161/circulationaha.109.853119

Cites

4 of 4 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 4 references

Cited by

See all 245

Metadata

Authors
Eikelboom, J. W., & Weitz, J. I.
Venue
Circulation
Published
2010-04-06
Volume
121
Issue
13
Pages
1523-1532
ISSN
  • 0009-7322 (ISSN-L)
  • 1524-4539
OpenAlex
W4245765453
Cited by
245
References
4
FWCI
28.13
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: New Anticoagulants. https://app.cochat.ai/papers/10.1161/circulationaha.109.853119
The paper
Eikelboom, J. W., & Weitz, J. I. (2010). New Anticoagulants. Circulation. https://doi.org/10.1161/circulationaha.109.853119

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.